AMENDMENTS TO THE CLAIMS

Claims 1-25 (Canceled):

26. (Currently Amended) A purified peptide ~~having~~ consisting of SEQ ID NO: 2 or a homologous peptide wherein said homologous peptide contains one conservative mutation ~~derivative thereof~~, wherein said ~~derivative is capable of binding~~ peptide binds to the IL-2β chain or the monoclonal antibodies produced by H2-8 hybridoma.

27. (Currently Amended) The peptide of Claim 26, ~~having~~ wherein said peptide consists of SEQ ID NO.: 2.

28. (Currently Amended) The peptide of Claim 26, wherein said peptide is said homologous peptide ~~contains one or more conservative mutation~~.

29. (Currently Amended) The peptide of Claim 28, wherein said conservative mutation is a replacement of ~~one or more~~ a non-polar ~~R-groups~~ R-group by ~~other~~ another non-polar ~~R-groups~~ R-group.

30. (Currently Amended) The peptide of Claim 28, wherein said conservative mutation is a replacement of ~~one or more~~ a uncharged non-polar ~~R-groups~~ R-group by ~~other~~ another uncharged non-polar ~~R-groups~~ R-group.

31. (Currently Amended) The peptide of Claim 28, wherein said conservative mutation is a replacement of ~~one or more~~ a charged polar ~~R-groups~~ R-group by ~~other~~ another charged polar ~~R-groups~~ R-group.

32. (Previously Presented) The peptide of Claim 28, wherein Lys is substituted for Arg, or vice versa so that a positive charge is maintained.

33. (Previously Presented) The peptide of Claim 28, wherein Glu is substituted for Asp, or vice versa so that a negative charge is maintained.

34. (Previously Presented) The peptide of Claim 28, wherein Asp is substituted for Glu.

35. (Previously Presented) The peptide of Claim 28, wherein one or more Ser is substituted for Thr.

36. (Previously Presented) The peptide of Claim 28, wherein one or more Gln is substituted for Asn.

37. (Currently Amended) ~~The peptide of Claim 26, wherein said peptide has a sequence~~ A purified peptide consisting of SEQ ID NO.: 4 or a homologous peptide wherein said homologous peptide contains one conservative mutation ~~derivative thereof~~, wherein said ~~derivative is capable of binding~~ peptide binds to the IL-2β chain or the monoclonal antibodies produced by H2-8 hybridoma.

38. (Currently Amended) The peptide of Claim 37, ~~having~~ wherein said peptide consists of SEQ ID NO.: 4.

39. (Currently Amended) The peptide of Claim 37, wherein said peptide is said homologous peptide ~~contains one or more conservative mutation~~.

40. (Currently Amended) The peptide of Claim 39, wherein said conservative mutation is a replacement of ~~one or more~~ a non-polar ~~R-groups~~ R-group by ~~other~~ another non-polar ~~R-groups~~ R-group.

41. (Currently Amended) The peptide of Claim 39, wherein said conservative mutation is a replacement of ~~one or more~~ a uncharged non-polar ~~R-groups~~ R-group by ~~other~~ another uncharged non-polar ~~R-groups~~ R-group.

42. (Currently Amended) The peptide of Claim 39, wherein said conservative mutation is a replacement of ~~one or more~~ a charged polar ~~R-groups~~ R-group by ~~other~~ another charged polar ~~R-groups~~ R-group.

43. (Previously Presented) The peptide of Claim 39, wherein Lys is substituted for Arg, or vice versa so that a positive charge is maintained.

44. (Previously Presented) The peptide of Claim 39, wherein Glu is substituted for Asp, or vice versa so that a negative charge is maintained.

45. (Previously Presented) The peptide of Claim 39, wherein Asp is substituted for Glu.

46. (Previously Presented) The peptide of Claim 39, wherein one or more Ser is substituted for Thr.

47. (Previously Presented) The peptide of Claim 39, wherein one or more Gln is substituted for Asn.

48. (Currently Amended) The peptide of Claim 37, wherein said derivative is a ~~homolgous~~ homologous peptide that induces SHC phosphorylation or induces the SHC/MAPK pathway.

49. (Currently Amended) The peptide of Claim 26, wherein said derivative is a ~~homolgous~~ homologous peptide that induces SHC phosphorylation or induces the SHC/MAPK pathway.

50. (New) A method of inducing SHC phosphorylation comprising administering to a subject in need thereof an effective amount of the peptide of Claim 26.

51. (New) A method of inducing the SHC/MAPK pathway comprising administering to a subject in need thereof an effective amount of the peptide of Claim 26.

52. (New) A method of inducing SHC phosphorylation comprising administering to a subject in need thereof an effective amount of the peptide of Claim 37.

53. (New) A method of inducing the SHC/MAPK pathway comprising administering to a subject in need thereof an effective amount of the peptide of Claim 37.

SUPPORT FOR THE AMENDMENTS

Claims 1-25 were previously canceled.

Claims 26-31, 37-42, 48, and 49 have been amended.

Claims 50-53 have been added.

The amendment of Claims 26 and 37 is by previously pending Claims 26 and 37, as well as the specification at, for example, pages 12-14. Support for the amendment of Claims 27-31, 38-42, and 49 is provided by original Claims 16-25 and page 7, line 15 to page 32, line 7 (for example page 7, lines 17-20 and page 8, lines 13-16). New Claims 50-53 are supported by original Claim 25.

Applicants note that Claims 50-53 are drawn to method claims that depend from originally presented product claims. As such, even if the Examiner were to hold these newly added claims as being non-elected by original presentation, upon a finding of allowability of Claims 26 and 37 the newly added Claims 50-53 shall be rejoined and examined (MPEP §821.04).

The specification has been amended to change the title to reflect the scope of the presented invention. The specification has also been amended to include the biological deposit information for the H2-8 hybridoma.

No new matter has been added by the present amendments.